Plain-English translation of NCT06380101 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a medical food called Nonessential Amino Acid Restriction (NEAAR) to see if it can help patients with advanced rectal cancer tolerate their standard cancer treatment better. All participants will receive this special medical food while undergoing chemotherapy and short-course radiation therapy, which are the normal treatments for this type of cancer. The study wants to find out if the treatment is safe, easy to follow, and if patients can stick with it.
Standard treatments for advanced rectal cancer can be hard on the body and cause side effects. Researchers believe this specially designed medical food might help patients handle the treatment better and improve their overall health during cancer care.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the special NEAAR medical food to use at home while undergoing your standard cancer treatment (radiation and chemotherapy). You will have regular visits with the study team who will check how well you're tolerating the treatment, monitor your health, and ask about any side effects or challenges you're experiencing. The study will last for the duration of your cancer treatment and the researchers will track how safe and well-tolerated the medical food is.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States
Sponsor
University of South Florida
Enrollment target
~30 participants
Started
September 2023
Primary completion
December 2026
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Richard R Tuli, MD
University of South Florida
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.